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Abbreviations and Textual Footnotes 
CTX chlorotoxin 
CPP cell-penetrating peptides 
kB1 kalata B1 
MCoTI-I Momordica cochinchinensis trypsin inhibitor-I 
MCoTI-II Momordica cochinchinensis trypsin inhibitor-II 
SPR surface plasmon resonance 
Fmoc fluorenylmethyloxycarbonyl 
SPPS solid-phase peptide synthesis 
RP-HPLC reversed-phase high-performance liquid chromatography 
NMR nuclear magnetic resonance (NMR) 
LC-MS liquid chromatography-mass spectrometry 
HeLa human cervical carcinoma cells 
DMEM Dulbecco’s Modified Eagle Medium 
FBS fetal bovine serum 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
PBS phosphate buffered saline 
TB trypan blue 
POPC 1-palmitoyl-2-oleoylphosphatidylcholine 
POPS 1-palmitoyl-2-oleoylphosphatidylserine 
SUB Small unilamellar vesicle 
TOCSY Total Correlation Spectroscopy 
NOESY Nuclear Overhauser Effect Spectroscopy 
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Abstract  
Chlorotoxin (CTX), a disulfide-rich peptide from the scorpion Leiurus quinquestriatus, has 
several promising biopharmaceutical properties, including preferential affinity for certain cancer 
cells, high serum stability, and cell penetration. These properties underpin its potential for use as 
a drug design scaffold, especially for the treatment of cancer; indeed, several analogues of CTX 
have reached clinical trials. Here, we focus on its ability to internalize into cells – a trait 
associated with a privileged sub-class of peptides called cell-penetrating peptides – and whether 
it can be improved through conservative substitutions. Mutants of CTX were made using solid-
phase peptide synthesis and internalization into human cervical carcinoma (HeLa) cells was 
monitored by fluorescence and confocal microscopy. CTX_M1 (i.e. [K15R/K23R]CTX) and 
CTX_M2 (i.e. [K15R/K23R/Y29W]CTX) mutants showed at least a 2-fold improvement in 
uptake compared to CTX. We further showed that these mutants internalize into HeLa cells 
largely via an energy-dependent mechanism. Importantly, the mutants have high stability, 
remaining intact in serum for over 24 h; thus, retaining the characteristic stability of their parent 
peptide. Overall, we have shown that simple conservative substitutions can enhance the cellular 
uptake of CTX, suggesting that such type of mutations might be useful for improving uptake of 
other peptide toxins.  
 
 
5 
 
Cell-penetrating peptides (CPPs) are able to traverse biological membranes and have broad 
utility in drug delivery.1-3 The mechanism by which these peptides are internalized into cells 
varies, but appears to be influenced by their structural and chemical features (e.g. amino acid 
composition) and the cell membrane properties of their target cell (e.g. lipid and membrane 
protein composition).4-7 Specifically, CPPs generally have a high content of positively charged 
amino acids, such as lysine or arginine, and/or display patches of hydrophobic amino acids that 
are required for internalization.8  
 
CPPs have been used successfully as tools to deliver drugs into cells. Some advantages of CPPs 
are low toxicity, the ability to be internalized by different types of cells, and the ability to deliver 
a wide range of cargoes,9 including nucleic acids,10-11 nanoparticles12 and small molecules.13 For 
instance, TAT, one of the most widely studied CPPs, has been used to deliver doxorubicin (an 
anticancer drug) to human ovarian carcinoma cells14 and to deliver peptide-blockers of c-Jun 
NH2-terminal kinase to intracellular compartments to block β-cell apoptosis.15 However, CPPs 
have some disadvantages, including poor stability in biological systems, which can limit their 
uptake.16  
 
Disulfide-rich peptides are typically very stable and have compact structures. Several disulfide-
rich peptides, including those derived from plants and animal venoms, have been reported to be 
internalized by cells and have been classified as CPPs.17-19 For example, the plant-derived 
cyclotides kalata B1 (kB1) and Momordica cochinchinensis trypsin inhibitors I and II (MCoTI-I 
and MCoTI-II), as well as their analogues, have been shown to enter mammalian cells and have 
been proposed to be promising scaffolds not only for stabilizing bioactive peptides but also for 
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drug delivery.19-22 Examples of venom-derived CPPs include crotamine, from the South 
American Rattlesnake, which shows nuclear localization after being internalized by cells,23 and 
maurocalcine, from the venom of the scorpion Scorpio maurus palmatus, which binds to the 
intracellular ryanodine receptor and triggers internal Ca2+ release seconds after being applied 
extracellularly.17, 24-25 
 
Another venom-derived disulfide-rich CPP is the 36-amino acid peptide chlorotoxin (CTX),26 
from the Israeli scorpion Leiurus quinquestriatus (Figure 1).27 CTX is particularly well-known 
as a ligand for targeting cancer cells, which has led to its development into imaging probes that 
can distinguish tumorigenic from non-tumorigenic tissue.28-29 'Tumor paint', an analogue of CTX 
conjugated to the fluorescent dye Cy5.5™, is one such imaging agent.29 CTX and CTX-
conjugated nanoparticles have also been used as vehicles to deliver drugs and therapeutic 
macromolecules (e.g. DNA, siRNA) selectively to cancer cells.30 Despite widespread interest in 
CTX for its ability to bind preferentially to cancer cells,28-36 relatively little is known about its 
ability to penetrate cells – a desirable pharmaceutical trait that could be utilized in drug 
development. Fundamental questions that currently remain unanswered include the extent of 
CTX uptake compared to other CPPs and whether its internalization is a property that can be 
tuned.  
 
In this study, CTX and two analogues (CTX_M1 and CTX_M2) were synthesized and used to 
examine the effect of increasing the number of arginine and tryptophan residues on cellular 
uptake. These mutations, although conservative in nature, have been shown to affect, and in 
some cases, substantially improve cellular uptake of peptides.37-42 For example, we recently 
7 
 
showed that mutation of both K9 and K10 to arginine residues resulted in a 2-fold enhancement 
in cellular uptake of MCoTI-II.43 In the current study, CTX analogues were labeled with either 
Alexa Fluor® 488 or Cy5.5™ and their internalization by HeLa cells examined using flow 
cytometry and confocal microscopy. In addition, the ability of the analogues to bind model lipid 
membranes was measured using surface plasmon resonance (SPR). Our findings suggest that 
internalization of CTX can be improved by increasing the arginine, and to a lesser extent 
tryptophan, content. The amount of peptide able to be internalized is also affected by the 
attached fluorescent dye. Finally, internalization of CTX and its analogues is mediated largely by 
an energy-dependent mechanism. Understanding the cell-penetrating ability of CTX, including 
by defining the roles of specific residues, could enable future applications of CTX as a delivery 
scaffold.  
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Experimental Procedures 
Synthesis and purification 
CTX and analogues were synthesized on a Symphony Multiplex automated synthesizer using N-
(9-fluorenyl)methyloxycarbonyl (Fmoc) solid-phase peptide synthesis (SPPS) chemistry and 
purified.44 After assembly, linear protected peptides were cleaved from the resin using 95:2.5:2.5 
TFA/TIPS (triisopropylsilane)/water. The Cys-reduced peptides were purified using C18 
columns by reversed-phase high performance liquid chromatography (RP-HPLC), as described 
previously. Briefly, a linear gradient of Buffer B (90% v/v CH3CN; 9.95% v/v H2O; 0.05% v/v 
CF3COOH) was mixed with Buffer A (99.95% v/v H2O; 0.05% CF3COOH) at 8 mL/min flow 
rate. 
 
Folding, purification and structural analysis 
Reduced CTX at 0.1 mg/mL was oxidized in a buffer containing 0.1 M Tris-HCl pH 7.8, 0.2 M 
NaCl, 5 mM reduced glutathione and 0.5 mM oxidized glutathione for 16–20 h at room 
temperature. CTX analogues were oxidized in the same buffer with the addition of 15% (v/v) 
isopropanol. The oxidized peptides were purified using RP-HPLC at either a 3 mL/min or 8 
mL/min flow rate depending on the column. The structures of folded peptides were confirmed 
using 1H nuclear magnetic resonance (NMR) spectroscopy, as described previously.45 Briefly, 
peptides were dissolved in H2O/D2O (9:1, v/v). To determine the chemical shifts of the peptides, 
NMR spectra were recorded on a Bruker Avance-600 MHz NMR spectrometer at 298 K. The 
mixing time was 80 ms and 200 ms for TOCSY and NOESY experiments, respectively. Spectra 
were internally referenced to 2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS) at 0.00 ppm. 
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Cy5.5™ labeling 
CTX and analogues were labeled with Cy5.5™ (GE Healthcare). Peptides at 1 mg/mL dissolved 
in 0.1 M sodium carbonate pH 9.3 (1 mL) were added to one vial of dye and incubated at room 
temperature for 3 h. The labeled and unlabeled peptides were separated using RP-HPLC. Purity 
of monolabeled peptide was confirmed by analytical RP-HPLC and liquid chromatography-mass 
spectrometry (LC-MS). The peptide concentration was determined by measuring the absorbance 
at 678 nm (ε678=250000 M-1 cm-1). Peptide stocks (TAT, TAT-N, CTX and CTX_M1) were 
dissolved in water or with the addition of 5% v/v dimethyl sulfoxide (CTX_M2), before being 
stored at -20°C until use. 
 
Alexa Fluor® 488 labeling 
CTX and analogues were labeled with Alexa Fluor® 488, as described previously.43 Briefly, 
peptide dissolved in 0.1 M sodium bicarbonate buffer (pH 8.0) was incubated with 2 mol 
equivalent of Alexa Fluor® 488 (Life Technologies) for 3 h at room temperature. Then, labeled 
and unlabeled peptides were separated using RP-HPLC. The purity of the monolabeled peptide 
was confirmed by analytical RP-HPLC and LC-MS. The concentration of the monolabeled 
peptides was determined by measuring their absorbance at 495 nm (A495) and considering the 
molar extinction coefficient of Alexa Fluor® 488 at 495 nm (ε495) as 71000 M-1 cm-1. Peptides 
were dissolved in water (TAT, TAT-N, CTX and CTX_M1) or with the addition of 5% v/v 
dimethyl sulfoxide (CTX_M2), before being stored at -20°C. 
 
Cell culture 
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Human cervical carcinoma cells (HeLa) were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS). Cells were supplemented with 1% 
(v/v) antibiotic/antimitotic and incubated at 37ºC with 5% CO2. hCMEC/D3 cells were a 
generous gift from Pierre-Olivier Couraud (INSERM, France). hCMEC/D3 cells were 
maintained at 37 ºC in a humidified incubator (5% CO2/95% O2) in endothelial basal medium-2 
supplemented with vascular endothelial growth factor (0.025% v/v), insulin-like growth factor 1 
(0.025% v/v), epidermal growth factor (0.025% v/v), basic fibroblast growth factor (0.1% v/v), 
hydrocortisone (0.01% v/v), ascorbic acid (0.01% v/v), FBS (0.1% v/v), HEPES (1M, pH 7.4, 
1% v/v) and penicillin-streptomycin (1% v/v). The cells were seeded at 50,000 cells/cm2 onto 
culture flasks/plates coated with rat tail collagen type I. 
 
Cytotoxicity assay 
The cytotoxicity of native CTX and its analogues was measured and analyzed as described 
previously.44 In brief, we used the transformation of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to insoluble formazan crystals by metabolic active cells as a means 
of detecting cell viability. The insoluble crystals were solubilized using dimethyl sulfoxide and 
the absorbance (A570) read using a spectrophotometer; the resulting absorbance was directly 
proportional to the number of living cells per well. To evaluate the toxic effect of CTX and 
analogues, each peptide was incubated with 103 HeLa cells for 2 h using concentrations ranging 
from 0 to 50 µM. Triton X-100 at 0.01% (v/v) was used as a positive control. 
 
Serum stability  
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The stability of peptides was examined using a modified version of a previously described 
protocol.22 Human male serum (Sigma-Aldrich) was centrifuged at 13,000 rpm for 10 min to 
remove lipids, and the supernatant was collected and incubated at 37°C for at least 10 min. The 
reaction was initiated by the addition of the peptide to the serum to a final peptide concentration 
of 20 µM. The incubation time points were 0, 2, 6, 12 and 24 h. Controls in phosphate buffered 
saline (PBS) were included. The reaction was stopped by denaturing the serum proteins with 
urea at a final concentration of 3 M at 4°C for 10 min, followed by the addition of trichloroacetic 
acid (final concentration of 7% v/v) and incubation at 4°C for 10 min to precipitate serum 
proteins. For each sample, the supernatant was collected after a 10-min centrifugation at 13,000 
rpm, and subsequently analyzed using analytical RP-HPLC with a 2%/min gradient of 90% (v/v) 
acetonitrile, 9.95% (v/v) water and 0.05% (v/v) trifluoroacetic acid. Triplicates were performed 
for each experiment. 
 
Flow cytometry analysis  
A BD FACSCanto II flow cytometer was used to quantify the fluorescence of Alexa Fluor® 488 
(488 nm excitation laser and 530/30 band-pass filter) and Cy5.5 (633 nm excitation laser, 780/60 
band-pass filter). HeLa cells or hCMEC/D3 cells were seeded in a 24-well plate (105 cells/well) 
1 day before the assay. Cells were pre-incubated with CTX or analogues (6 µM) for 1 h at either 
4°C or 37°C, followed by washing with cold PBS. The cells were then trypsinized and the cell 
pellet resuspended in 500 µL of cold PBS, as described previously.43, 46 Using a cytometer, the 
mean fluorescence emission of 10,000 cells was measured before and after the addition of 160 
µg/mL of trypan blue (TB) for Alexa Fluor® 488-labeled peptides. 
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Confocal microscopy 
The internalization of conjugated peptides was measured in live cells using a confocal 
microscope. The day before confocal microscopy was performed, 6×104 cells/well were seeded 
in an 8-well coverglass plate. Then, incubated with 6 µM of conjugated peptide for 1 h at either 
4°C or 37°C. Following incubation, live cell images were captured at room temperature using an 
inverted LSM 510 (Zeiss) confocal laser scanning microscope, and subsequently analyzed using 
ImageJ software.  
 
SPR analysis 
SPR experiments were conducted at room temperature with a L1 biosensor chip in a Biacore 
3000, as described previously.47-48 Synthetic lipids 1-palmitoyl-2-oleoylphosphatidylcholine 
(POPC) and 1-palmitoyl-2-oleoylphosphatidylserine (POPS) obtained from Avanti Polar Lipids 
were used to prepare model membranes. Small unilamellar vesicles (SUVs) with a diameter of 
50 nm and composed of POPC or POPC/POPS (4:1 molar ratio) were obtained by freeze-thaw 
and sized by extrusion, following previously described protocols.49 SUVs were deposited onto 
the L1 chip surface and CTX and its analogues were analyzed for their membrane-binding 
affinities to POPC and POPC/POPS (4:1) lipid bilayers, as described previously.47 Peptide and 
SUV samples were prepared in running buffer (10 mM HEPES containing 150 mM NaCl, pH 
7.4). Peptide affinity for synthetic bilayers was analyzed as described previously.47 
13 
 
Results 
Peptide design, structural characterization and labeling 
Electrostatic interactions between basic amino acids in CPPs and negatively charged molecules 
at the surface of cell membranes have been recognized as important for the uptake of positively 
charged CPPs. Furthermore, arginine residues seem to favor the internalization of peptides 
compared to lysine residues.37-39 CTX has three lysine (K15, 23 and 27) and three arginine 
residues (R14, 25 and 36) in its sequence. To improve the uptake of CTX, K15 and K23 were 
replaced with arginine residues. The side chain of K27 in CTX was not modified in any of the 
analogues to allow for amine-coupled conjugation of the fluorescent probe required for the 
internalization assay. K27 was selected as the conjugation site based on a previous study of an 
optimized analogue of CTX for tumor imaging and targeted therapy.45 The importance of amino 
acids with hydrophobic side chains in CPPs has been reported,40-42 thus tryptophan was also 
incorporated in the CTX sequence (Y29W). Y29 was chosen as the mutation site because of its 
structural similarity to Trp. The sequences of CTX and two analogues used in this study, as well 
as their disulfide bond connectivities are shown in Figure 1B.  
 
The various peptides were synthesized using SPPS chemistry, folded and then purified using RP-
HPLC. The structures of pure CTX and its analogues were characterized using 1H NMR 
spectroscopy. Total correlation spectroscopy (TOCSY) and nuclear Overhauser effect 
spectroscopy (NOESY) spectra were recorded at 600 MHz at 298 K and sequence-specific 
assignments were obtained. Based on the αH NMR chemical shifts, we found that CTX and its 
analogues have similar overall three-dimensional structures (Figure 2A), confirming that the 
substitutions did not have an effect on the tertiary structure. 
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The peptides were labeled with either the dye Alexa Fluor® 48843 or the near-infrared dye 
Cy5.5™29 to allow their internalization by HeLa cells to be monitored. Only pure monolabeled 
peptides were used, with their identity and purity confirmed by analytical RP-HPLC and LC-MS. 
 
Stability of peptides 
CTX is a very stable peptide that can resist enzymatic proteolysis in vitro and in vivo.45 To 
compare the relative stabilities of CTX and its analogues, peptides were incubated in human 
serum containing proteolytic enzymes and in PBS at 37°C, and monitored over time. As 
expected, PBS did not have an effect on peptide stability (data not shown). A version of CTX 
without disulfide bonds but with all cysteines replaced with L-α-aminobutyric acid (Abu)44 was 
also included as a control, representing a peptide that degrades rapidly in serum. Consistent with 
previous studies,44-45 CTX was highly stable, with around 90% of intact peptide remaining after 
24 h of incubation, and the disulfide-bond deleted analogue of CTX was degraded in less than 4 
h (Figure 2B). CTX analogues showed levels of stability similar to that of CTX (Figure 2B).  
 
Cytotoxicity analysis 
Cytotoxicity of the compounds was assessed to determine a suitable working peptide 
concentration for our internalization studies. Although CTX has been reported to be non-toxic to 
mammalian cells,44, 50 in the present study cell viability was tested to investigate whether the 
replacement of lysine and tyrosine residues affects the cytotoxicity of CTX analogues. Neither 
CTX nor its analogues were cytotoxic to HeLa cells up to a peptide concentration of 50 μM, as 
shown in Figure 2C. 
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Internalization of CTX and analogues labeled with Alexa Fluor® 488 and Cy5.5™ 
Quantification of cellular uptake was investigated using fluorophore-labeled peptides. The 
experiments were performed with HeLa cells at 4°C and 37°C, and the fluorescence emissions of 
Alexa Fluor® 488 and Cy5.5™ were measured using flow cytometry. As in a previous study,43 
two short peptides were used as controls: TAT (YGRKKRRQRRRPPQG-amide), a 14-mer 
derived from the region of the HIV-1 Tat protein, which is known for its ability to penetrate 
cellular membranes; and, TAT-N (YGGGKGGQGGGPPQG-amide), in which all cationic 
residues from the TAT peptide were replaced with glycine, with the exception of K5 (which was 
preserved to enable conjugation to the fluorophore). TAT-N was used as a measure of poor 
internalization by HeLa cells. Figure 3 shows a clear difference in terms of the uptake ratio 
between TAT and TAT-N, supporting the use of these peptides as controls for high and low 
uptake, respectively. A fixed concentration of 6 µM was used to compare internalization of 
peptides after a 1-h incubation. 
 
Figure 3A shows the internalization of peptides labeled with Alexa Fluor® 488 at 37°C. CTX 
was able to enter cells but to a similar extent as TAT-N, which was used as a marker of poor 
cellular uptake. The introduction of two arginine residues into the sequence of CTX (CTX_M1) 
improved cellular uptake by approximately 2-fold. However, the introduction of an additional 
tryptophan residue (CTX_M2) did not further improve internalization, as the internalization rate 
is similar to CTX_M1, suggesting that the two arginine residues introduced into the sequence 
have the greatest effect on cell uptake of CTX. To evaluate whether the differences in uptake 
ratio were due to membrane binding, the intensities of the fluorescence reading before and after 
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adding trypan blue (a membrane-impermeable quencher) were measured. No significant 
differences in uptake in HeLa cells were observed before and after adding trypan blue (data not 
shown), suggesting that CTX or its analogues were not bound to the cellular membrane. We also 
determined the uptake of CTX and its analogues in hCMEC/D3 cells, which unlike HeLa cells, 
are endothelial in nature but are interesting because they are commonly used to mimic the human 
blood-brain barrier.51 As shown in Supplementary Figure S1, the relative uptake of CTX and its 
analogues compared to TAT and TAT-N are similar in hCMEC/D3 cells and HeLa cells, 
suggesting that the uptake efficiencies of CTX_M1 and CTX_M2 relative to CTX might be 
shared between epithelial and endothelial cells. 
 
Figure 3B shows the internalization of peptide labeled with Cy5.5™ at 37°C by HeLa cells. 
CTX labeled with Cy5.5™ showed an improved ratio of internalization compared to TAT-N. 
CTX_M1 showed improved internalization by about 80% compared to CTX and the introduction 
of tryptophan (CTX_M2) also improved internalization, with uptake that was 80% that of TAT. 
In this case we could not use trypan blue to determine whether peptide membrane binding 
contributed to the observed fluorescence because trypan blue absorbs light at a similar 
wavelength as Cy5.5™.  
 
Internalization of CTX and its analogues was examined at 4°C. At 4°C all energy-dependent 
internalization processes are inhibited or slowed and the lipid bilayer exhibits increased rigidity. 
Figures 3C and D show the internalization of peptides labeled with Alexa Fluor® 488 and 
Cy5.5™ at 4°C, respectively. Apart from TAT labeled with Alexa Fluor® 488, which was able 
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to enter cells at 4°C, the other peptides were unable to penetrate cells to any significant degree at 
the lower temperature.  
 
Peptides were observed using confocal microscopy of live HeLa cells to confirm internalization. 
Figure 4 shows CTX, CTX_M1 and CTX_M2 labeled with Alexa Fluor® 488 and Cy5.5™ after 
a 1-h incubation at 37°C. The internalized peptides display a punctate distribution inside cells, 
consistent with endosomal localization, and no fluorescence was detected when the 
internalization experiments were performed at 4°C (data not shown). This result confirms our 
data obtained using FACS, and supports the hypothesis that the CTX peptides are internalized by 
cells and not restricted to the cell membrane. 
 
Membrane binding studies using SPR 
Interaction with lipids of cell membranes has been reported to be an important step in the 
internalization of some CPPs.20, 52 We were interested in the contribution of lipid binding to the 
cellular uptake of CTX and its analogues. Mammalian cell membranes have a fluid and neutral 
outer leaflet in which phospholipids containing a phosphatidylcholine (PC)-head group are most 
abundant; therefore, POPC phospholipid, which forms bilayers with a fluid phase at room 
temperature, was used to mimic the neutral charge and the fluid phase characteristic of these 
membranes. Negatively charged phosphatidylserine (PS)-containing phospholipids are also 
present in mammalian cells, and are more abundant in cancerous cell membranes than in normal 
cells. Thus, to evaluate if electrostatic attractions between the lipid membrane and positively 
charged peptides are important, the binding of the CTX peptides to lipid bilayers composed of 
POPC/POPS (80:20) was also studied by SPR using a L1 chip. This method monitors peptide 
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binding to lipid bilayers in real time. Concentrations up to 200 µM of CTX or analogues were 
used. Although Figures 5A, B and C show peptide binding to lipids (POPC) increases with 
higher peptide concentration, importantly the amount of peptide bound, as indicated by the 
peptide to lipid ratio, is low. Specifically, when the membrane affinities of CTX and analogues 
are compared with the affinities of other peptides that we have previously characterized, for 
example kalata B1 or TAT,20, 47 the affinity of CTX and its analogues to the tested lipid bilayers 
is low. The same trend was observed when the POPC/POPS lipid system was used (data not 
shown). These results suggest that direct binding to POPC or POPS lipids plays a minor role in 
the uptake of CTX and its analogues.  
 
To examine whether Alexa Fluor® 488 and Cy5.5™ play a role in the lipid-binding properties of 
CTX and CTX_M1, labeled and unlabeled peptides (25 µM) were compared on their ability to 
bind to POPC/POPS membranes. Figure 6A shows the binding of unlabeled peptides and 
peptides labeled with Alexa Fluor® 488 to POPC/POPS membranes. The results show a slight 
difference between labeled and unlabeled peptides, suggesting that this dye might have a small 
effect on the binding of the peptides to negatively charged membranes. As shown in Figure 6B, 
Cy5.5™ causes a 2-fold and 3-fold increase in the binding of CTX and CTX_M1, respectively, 
to POPC/POPS membranes compared to the unlabeled peptides. The difference between Alexa 
Fluor® 488- and Cy5.5™-labeled peptides is also observed for the internalization of peptides 
into HeLa cells, supporting the hypothesis that the dye used to investigate CPP uptake can 
modify their properties. 
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Discussion 
The aim of this work was to investigate the cell-penetrating properties of CTX. In particular, we 
were interested in the effect of conservative substitutions of lysine to arginine as well as tyrosine 
to tryptophan. Our results show that the cellular uptake of CTX can be improved by replacing 
two lysine residues with arginine residues, and that these substitutions do not affect the stability 
or structure of CTX. This knowledge can guide further molecular optimization of the cell-
penetrating properties of CTX. Furthermore, the arginine-rich version of CTX has the potential 
to be used as a scaffold to deliver compounds selectively to, and then into, cancer cells. 
 
We found that replacing two lysine residues (K15 and K23) with arginine residues increased the 
internalization of CTX 2-fold. Arginine residues are believed to facilitate cellular uptake of a 
parent peptide because their guanidinium cationic group can potentially form favorable 
interactions with surface-exposed components at the cell surface (via interactions with lipids, 
membrane proteins, etc).37-38, 53-55 Indeed, polyarginine peptides represent the simplest CPPs and 
have been used to deliver molecules intracellularly.56 Our finding that CTX can be modified by 
introducing arginines into its sequence, resulting in a more effective CPP, provides further 
confirmation that arginine residues are important facilitators of cellular uptake. In addition to 
positively charged residues, tryptophan has been shown to affect membrane translocation;40-42 
however, we found that the incorporation of a tryptophan residue at position 29 did not further 
enhance internalization of CTX_M1. This result is consistent with previous studies showing that 
both the positions of the tryptophan residues and the size of the hydrophobic patch they form 
affect cellular uptake efficiency.41 Additionally, we showed that the fluorescent dye used to 
investigate the mechanisms of cellular uptake and intracellular distribution of CTX can affect its 
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cell-penetration properties. This result is consistent with previous reports showing that the labels 
and cargoes attached to a CPP affect its localization and internalization.57-63 In our case, although 
the uptake of CTX and its analogues relative to one another is independent of the dye used (i.e. 
CTX < CTX_M1 ~ CTX_M2), the internalization of the peptides attached to Cy5.5™ is greater 
than that of their respective counterparts attached to Alexa Fluor® 488.   
 
Using two different temperatures (i.e. 4°C and 37°C), we observed that CTX and its analogues 
can be internalized by HeLa cells only at physiological temperature, suggesting that CTX enters 
cells via endocytosis – a receptor-mediated energy-dependent mechanism. This result is 
consistent with a previous study showing that radiolabeled CTX could enter D54 MG cells, 
which are human glioma cells, at 37°C but not 4°C.64 From the confocal images we observed 
that CTX and analogues have a punctate pattern of cellular distribution, suggesting that they 
follow an endocytic pathway after being internalized by HeLa cells. Furthermore, since CTX 
affinity for synthetic POPC and POPS lipids is low compared to other membrane binding 
peptides,24, 51 we hypothesize that CTX is carried into cells by other membrane components. 
 
CTX has several promising biopharmaceutical properties that underpin its potential as a drug 
design scaffold. One of these properties that has perhaps attracted the most interest from 
medicinal chemists is the ability to specifically target cancer cells, which has led to the 
development of CTX into imaging probes that can distinguish tumorigenic from non-tumorigenic 
tissue.28-29 Additionally, CTX is very stable (unlike peptides in general), a property that is 
retained by the improved arginine-rich CTX reported here. As CTX can also internalize into 
cells, we speculate that it represents a promising scaffold for the design of drugs that target 
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intracellular proteins for the treatment of a wide range of diseases including cancer. Interestingly, 
it was recently shown that the disulfide-rich peptide MCoTI-II could be re-designed to exhibit 
cellular uptake efficiency, comparable to that of TAT, by incorporating more drastic changes to 
its sequence22 than those applied in this study, suggesting that further improvements to the cell-
penetrating properties of CTX are possible.  
 
Although CTX has several promising biopharmaceutical properties, it also has limitations (which 
are typical of peptides in general65-66) that could restrict its therapeutic potential for now. For 
example, despite being taken up by cells, it appears that the majority of internalized CTX is 
trapped inside endosomes, restricting its delivery into the cytoplasm. Many other cell-penetrating 
peptides have also been reported to have this limitation, which is a major obstacle for peptide-
mediated intracellular drug delivery.67 Encouragingly, recent studies have shown that cell-
penetrating peptides can be modified to help them escape from endosomes; 67-68 thus, it might be 
possible to modify CTX to increase the cytosolic concentration after cellular uptake. Another 
limitation of peptides, including CTX,29, 69 is poor in vivo half-life due to rapid renal clearance 
(molecules <30 kDa are excreted rapidly by glomerular filtration). There are now several 
strategies available to overcome this limitation, including conjugation to polyethylene glycol or 
affinity tags that bind serum proteins, which have been successful in enhancing in vivo half-
life.70-71 For example, liraglutide (marketed as Victoza®), which is used for treatment of type II 
diabetes  or obesity, is an analog of the GLP-1 peptide. Compared to the parent compound, it 
contains an attached fatty acid molecule that increases it binding to serum albumin, resulting in 
slower degradation and reduced renal elimination. 
22 
 
Conclusion 
Here, we showed that cellular uptake of CTX could be improved by tuning its sequence – 
specifically by replacement of lysine with arginine residues. This mutagenesis strategy is 
conservative in nature and could, in principle, be applied to improve uptake of other toxins. In 
some cases, a conservative mutagenesis strategy is desirable to minimize effects on other 
properties of the parent peptide. Indeed, the analogues presented herein retained the structure, 
low toxicity and stability of CTX. Looking beyond CTX, there are many venom-derived peptides 
that have been recently reported to have high sequence similarity to CTX.72 These chlorotoxin-
like peptides might also serve as tuneable drug design scaffolds with potential for use in drug 
delivery. 
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Figure captions  
Figure 1. Three-dimensional structure of chlorotoxin and sequences of chlorotoxin and 
analogues. A. Schematic representation of chlorotoxin (PDB:1CHL) with the backbone colored 
white. Disulfide bonds and mutated residues are shown in stick format, labeled and colored grey. 
B. Sequence of chlorotoxin (CTX) and its analogues. Residues mutated to produce CTX_M1 and 
CTX_M2 are boxed. The disulfide bond connectivity of CTX and its analogues is shown at the 
bottom of the figure and the cysteines are numbered using Roman numerals. 
 
Figure 2. Characterization of structure, stability and cytotoxicity of chlorotoxin and 
analogues. A. The similar αH chemical shift values of chlorotoxin (CTX; circle) and the 
analogues, CTX_M1 (inverted triangle) and CTX_M2 (diamond), show that they adopt similar 
folds. B. The percentage of peptide remaining after a 24-h incubation in human serum at 37°C. 
The amount of peptide remaining was calculated by comparing the height of the elution peak of 
peptides incubated in human serum and that of peptides that had not been incubated. C. 
Cytotoxicity of CTX and its analogues to HeLa cells after a 1-h incubation. Cell viability was 
determined by the MTT assay. Controls with buffer and Triton X-100 at 0.01% (v/v) were used 
to establish 100% and 0% of cell survival, respectively. Data points are shown as mean ± SD of 
three experiments.  
 
Figure 3. Internalization of fluorescently labeled peptides into HeLa cells, as measured by 
flow cytometry. A. Internalization of peptides labeled with Alexa Fluor® 488 at 37°C. B. 
Internalization of peptides labeled with Cy5.5™ at 37°C. C. Internalization of peptides labeled 
with Alexa Fluor® 488 at 4°C. D. Internalization of peptides labeled with Cy5.5™ at 4°C. The 
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mean fluorescence emission intensity of 10,000 cells was measured at 488 nm for cells treated 
with Alexa Fluor® 488-labeled peptides and at 633 nm for cells treated with Cy5.5™-labeled 
peptides. Data are represented as mean ± SD of at least two independent experiments. The 
statistical analysis was performed using an ANOVA Tukey's multiple comparisons test by 
comparison of CTX_M1 and CTX_M2 with CTX (****p < 0.001). Relative fluorescence 
emission intensity was normalized to TAT at 37°C. 
 
Figure 4. Confocal microscopy images of live HeLa cells treated with fluorescently labeled 
peptides. Cells were incubated at 37°C for 1 h with Cy5.5™-labeled CTX (A), CTX_M1 (B) 
and CTX_M2 (C) or with Alexa Fluor® 488-labeled CTX (D), CTX_M1 (E), and CTX_M2 (F). 
Magnification of the cells is also shown (inset).  
 
Figure 5. Interaction of peptides with POPC model membranes, studied by SPR. Binding of 
CTX (A), CTX_M1 (B) and CTX_M2 (C) to POPC bilayers deposited onto an L1 chip. 
Sensorgrams were obtained upon injection of 25 µM, 50 µM, 100 µM and 200 µM of peptide 
over POPC bilayer over time, as indicated in panel (A). Peptides were injected for 180 s and 
dissociation followed for 800 s. The response signal was normalized and represented as P/L 
(peptide-to-lipid ratio) versus time. Despite evidence of some binding, when the membrane 
affinities shown in this figure are compared with the affinities of other peptides that we have 
previously characterized, for example kalata B1 or TAT,20, 47 the lipid affinity of CTX and its 
analogues is low. 
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Figure 6. Interaction of labeled and unlabeled peptides with POPC/POPS model 
membranes, studied by SPR. A. Comparison of the affinity of unlabeled peptides or labeled 
with Alexa Fluor® 488 (CTX and CTX_M1) for POPC/POPS membranes. B. Comparison of the 
affinity of unlabeled peptides or labeled with Cy5.5™ (CTX and CTX_M1) for POPC/POPS 
membranes. The response signal was normalized and represented as P/L (peptide-to-lipid ratio) 
versus time.  
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